Pharmacologie treatment options for non-insulin-dependent diabetes mellitus

Mayo Clinic Proceedings

Volumn 71, Issue 8, 1996, Pages 763-768

  Tan, Gerry H ^a   Nelson, Roger L ^b  

^a MAYO CLINIC ROCHESTER   (United States)

^b Chong Hua Hospital   (Philippines)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE; GLIPIZIDE; INSULIN; METFORMIN; SULFONYLUREA; ENZYME INHIBITOR; GLUCOSIDASE; SULFONYLUREA DERIVATIVE; TRISACCHARIDE;

ALGORITHM; DIET; DISEASE ASSOCIATION; EXERCISE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HOME MONITORING; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PERNICIOUS ANEMIA; REVIEW; RISK ASSESSMENT; TREATMENT PLANNING; BLOOD; BLOOD GLUCOSE MONITORING; COST; DRUG ANTAGONISM; ECONOMICS;

ACARBOSE; BLOOD GLUCOSE SELF-MONITORING; COSTS AND COST ANALYSIS; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; GLUCOSIDASES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; SULFONYLUREA COMPOUNDS; TRISACCHARIDES;

EID: 0030317624     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-6196(11)64841-6     Document Type: Article

References (26)

1. Huse DM, Oster G, Killen AR, Lacey MJ, Colditz GA. The economic costs of non-insulin-dependent diabetes mellitus. JAMA 1989;262:2708-2713
2. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med 1993; 329:977-986
3. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28:103-117
4. Zimmerman BR. Improvements in diabetes treatment [editorial]. MinnMed 1995; 78:46-48
5. DeFronzo RA. The triumvirate: -cell, muscle, liver; a collusion responsible for NIDDM. Diabetes 1988; 37:667-687
6. Henry RR, Wallace P, Olefsky JM. Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus. Diabetes 1986; 35:990-998
7. American Diabetes Association. The pharmacological treatment of hyperglycemia in NIDDM [consensus statement!. Diabetes Care 1995; 18:1510-1518
8. Lebovitz HE. Sulfonylurea drugs. In: Lebovitz HE, editor. Therapy for Diabetes and Related Disorders. 2nd ed. Alexandria (VA): American Diabetes Association, 1995: 116123
9. Gerich J. Oral hypoglycémie agents. N Engl J Med 1989; 321:1231-1245
10. Brodows RG. Benefits and risks with glyburide and glipizide in elderly NIDDM patients. Diabetes Care 1992; 15:75-80
11. Meinen CL, Knatterud GL, Prout TE, Klimt CR (for the University Group Diabetes Program). A study of the effects of hypoglycémie agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970; 19:789-830
12. Ohneda A, Maruhama Y, Itabashi H, Oikawa SI, Kobayashi T, Horigome K, et al. Vascular complications and longterm administration of oral hypoglycémie agents in patients with diabetes mellitus. Tohoku J Exp Med 1978; 124:205222
13. GroopLC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15:737-754
14. Jackson RA, Hawa MI, Jaspan JB, Sim BM, Disilvio L, Featherbe D, et al. Mechanism of metformin action in noninsulin-dependent diabetes. Diabetes 1987; 36:632-640
15. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15:755-772
16. Tomkin GH. Malabsorption of vitamin B12 in diabetic patients treated with phenformin: a comparison with metformin. BMJ 1973; 3:673-675
17. Campbell IW. Metformin and the sulfonylureas: the comparative risk. Horm Metab Res Suppl 1985; 15:105-111
18. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS) 13: relative efficacy of randomly allocated diet, sulfonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310:83-88
19. Bressler R, Johnson D. New pharmacological approaches to therapy of NIDDM. Diabetes Care 1992; 15:792805
20. Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med 1994; 121:928-935
21. Zimmerman BR. Practical aspects of intensive insulin therapy. Mayo Clin Proc 1996; 61:806-812
22. Peters AL, Davidson MB. Insulin plus a sulfonylurea agent for treating type 2 diabetes. Ann Intern Med 1991; 115:4553
23. Pugh JA, Wagner ML, Sawyer J, Ramirez G, Tuley M, Friedberg SJ. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis. Diabetes Care 1992; 15:953-959
24. Stern MP. Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents? Ann Intern Med 1996;124:110-116
25. Giugliano D, Quatraro A, Consoli G, Minei A, Ceriello A, De Rosa N, et al. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 1993; 44:107112
26. Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan D, Peterson CM. Tests of glycemia in diabetes. Diabetes Care 1995; 18:896-909